The cancer cell arises from normal precursors through a step-wise accumulation of genetic mutations. These oncogenic alterations endow malignant cells with the ability to grow without restraint, to ignore normal tissue boundaries, to recruit a supply of nutrients, and to metastaize. Although the study of cancer cells derived from patients has elucidated many fundamental principles of oncology, the critical changes that initiate cancer have been difficult to define with his approach. Additional progress in the diagnosis and treatment of cancer requires a more detailed and precise understanding of the subtle alterations that transform normal cells into cancer cells. As a postdoctoral fellow I have elucidated the role of telomerase activity is required for the continued growth of cancer. Manipulating telomerase, oncogenes, and tumor suppressors, I have converted normal human cells to tumorigenicity, thereby creating human tumor cells with a defined genetic constitution for the first time. These observations form the foundation for the studies presented in this application to use telomerase as an important component of new model systems of human cancer. I propose to create new cell-based models of the common epithelial including breast, prostate, and lung cancer and to use these model systems to define the critical pathways that convert normal cells into cancer. I will use these model systems to study the molecular systems with information derived from patient samples and clinical outcome data to generate the foundations of a new approach to the molecular staging of cancer. Taken together, these studies will permit me to identify the crucial intracellular pathways that initiate cancer and to validate molecular targets to which to develop new anti-neoplastic agents. A Mentored Research Scientist Development Award will provide me the opportunity to take advantage of the mentorship of Dr. Robert Weinberg and the unique resources of the Whitehead Institute to develop these new systems and to broaden my research experiences as I make the crucial transition to an independent investigator.
| Tu, Daqi; Zhu, Zehua; Zhou, Alicia Y et al. (2013) Structure and ubiquitination-dependent activation of TANK-binding kinase 1. Cell Rep 3:747-58 |
| Majumder, Pradip K; Grisanzio, Chiara; O'Connell, Fionnuala et al. (2008) A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 14:146-55 |
| Nieto, Maria; Finn, Stephen; Loda, Massimo et al. (2007) Prostate cancer: Re-focusing on androgen receptor signaling. Int J Biochem Cell Biol 39:1562-8 |
| Chen, Wen; Arroyo, Jason D; Timmons, Jamie C et al. (2005) Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Res 65:8183-92 |
| Masutomi, Kenkichi; Possemato, Richard; Wong, Judy M Y et al. (2005) The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A 102:8222-7 |
| Boehm, Jesse S; Hahn, William C (2005) Understanding transformation: progress and gaps. Curr Opin Genet Dev 15:13-7 |
| Hashimoto, Manabu; Kyo, Satoru; Masutomi, Kenkichi et al. (2005) Analysis of telomeric single-strand overhang length in human endometrial cancers. FEBS Lett 579:2959-64 |
| Hahn, W C (2005) Telomere and telomerase dynamics in human cells. Curr Mol Med 5:227-31 |
| Dong, Carolyn K; Masutomi, Kenkichi; Hahn, William C (2005) Telomerase: regulation, function and transformation. Crit Rev Oncol Hematol 54:85-93 |
| Arroyo, Jason D; Hahn, William C (2005) Involvement of PP2A in viral and cellular transformation. Oncogene 24:7746-55 |
Showing the most recent 10 out of 35 publications
